October 26, 2016
A California federal judge on Wednesday granted $23.8 million in attorneys' fees to Labaton Sucharow LLP and others serving as class counsel to investors who reached a $95 million settlement with Amgen Inc. over the company's alleged misstatements about two of its anti-anemia drugs.
July 20, 2016
Global biotechnology company Amgen Inc. has reached a $95 million settlement with investors over alleged misstatements about two of its anti-anemia drugs, according to settlement documents filed in California federal court Wednesday, bringing nearly a decade of class action litigation to a close.
November 08, 2011
The Ninth Circuit refused on Tuesday to decertify a class of shareholders in a case alleging Amgen Inc. misled investors about two top-selling anemia drugs, ruling the suit plausibly alleged the biotech company's statements were both false and material.